New Standard of Care for Induction Therapy in Previously Untreated MM

In a study with 474 patients, researchers found that the addition of bortezomib to lenalidomide and dexamethasone for induction therapy in previously untreated myeloma resulted in a statistically significant and clinically meaningful improvement in PFS as well as better OS.4


Continue Reading

The researchers concluded that this regimen had an acceptable safety and tolerability profile despite increased neurotoxicity. They reported that this may represent a new standard of care.

“We have made a huge leap in the last several months with a number of novel agents,” said hematologic oncologist Alexander Lesokhin, MD, who is an assistant attending physician at Memorial Sloan Kettering Cancer Center in New York, NY. “We are using mechanisms that have not previously been used in this disease and we are beginning to understand how better to use these

He said these new agents when combined appropriately should add a minimum of 2 to 3 years in terms of OS. In addition, he said these agents are improving patients’ quality of life because of their tolerable side-effect profiles.

“We are definitely extending survival and that is very meaningful. MM is heading into becoming a chronic disease. I think as we learn to use the monoclonal antibodies we will begin to see very durable remissions. We are heading there, but we still have more to go,” Dr Lesokhin said in an interview with Cancer Therapy Advisor.

References

  1. Plesner T, Arkenau H-T, Gimsing P, et al.  Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1/2 Study (GEN503) myeloma: therapy, excluding transplantation program [abstract 507]. Presented at: 57th American Society of Hematology (ASH) Annual Meeting & Exposition; December 5-8, 2015; Orlando, FL.
  2. Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 Tourmaline-MM1 Study (NCT01564537) [abstract 727]. Presented at: 57th American Society of Hematology (ASH) Annual Meeting & Exposition; December 5-8, 2015; Orlando, FL.
  3. Dimopoulos MA, Lonial S, White D, et al. Eloquent-2 update: a phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma – 3-year safety and efficacy follow-up [abstract 28. Presented at: 57th American Society of Hematology (ASH) Annual Meeting & Exposition; December 5-8, 2015; Orlando, FL.
  4. Durie B, Hoering A, Rajkumar SV, et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777 [abstract 25]. Presented at: 57th American Society of Hematology (ASH) Annual Meeting & Exposition; December 5-8, 2015; Orlando, FL.